Enliven Therapeutics Inc.
$23.97
(as of Jun 16, 11:21 AM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Enliven Therapeutics Inc.
Stock Price
$23.97
Ticker Symbol
ELVN
Exchange
NASDAQ
Industry Information for Enliven Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Company Description for Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Fundamentals for Enliven Therapeutics Inc.
Market Capitalization
$1,075,108,352
EBITDA
$-109,948,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.92
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
49,069,300
Percent Owned by Insiders
5.56%
Percent Owned by Institutions
103.43%
52-Week High
52-Week Low
Technical Indicators for Enliven Therapeutics Inc.
Analyst Ratings for Enliven Therapeutics Inc.
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
0
News About Enliven Therapeutics Inc.
Jun 16, 2025, 6:02 AM EST
Goldman Sachs initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) Monday with a Buy rating and a $37.00 price target, citing positive Phase 1 data for the company’s chronic myeloid leukemia (CML) treatment. See more.
Jun 13, 2025, 6:52 AM EST
(RTTNews) - Enliven Therapeutics, Inc. See more.
Jun 4, 2025, 4:48 PM EST
In trading on Wednesday, shares of Enliven Therapeutics Inc (Symbol: ELVN) crossed above their 200 day moving average of $22.39, changing hands as high as $22.52 per share. See more.
May 17, 2025, 12:40 PM EST
JonesResearch analyst Soumit Roy lowered the firm’s price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. See more.